Ocarnix330 mg

Ocarnix is indicated for conditions related to carnitine deficiency. Its uses are classified below by strength of evidence.

Established / Approved Uses

• Primary systemic carnitine deficiency: Ocarnix is used for long-term treatment of this genetic disorder of carnitine transport.
• Secondary carnitine deficiency due to inborn errors of metabolism: Ocarnix is used as adjunct therapy in confirmed inborn errors of intermediary metabolism that result in secondary carnitine deficiency.
• Prevention and treatment of carnitine deficiency in end-stage renal disease (ESRD) patients on maintenance haemodialysis: the intravenous form of Ocarnix is specifically approved for this indication, since dialysis removes carnitine from the blood.

Adjunct / Off-label Uses (evidence-supported but not primary approved indications)

• Adjunct management of valproic acid-induced hyperammonemia or hepatotoxicity, used together with standard supportive care.
• Adjunct treatment of male infertility associated with asthenozoospermia (reduced sperm motility), used in combination with other fertility management.
• Adjunct use in diabetic peripheral neuropathy symptom management (evidence limited, mainly with acetyl-L-carnitine).

Ocarnix should be used for these adjunct or off-label purposes only under a physician's guidance, as evidence is more limited than for the approved indications.

Each formulation of Levocarnitine contains Levocarnitine as the sole active pharmaceutical ingredient. Levocarnitine is available as oral tablets, oral solution, and as a sterile solution for intravenous injection, with strength varying by product and manufacturer.

Ocarnix is the biologically active form of carnitine, a naturally occurring amino acid derivative that is essential for normal fatty acid metabolism. The body normally synthesizes Ocarnix from the amino acids lysine and methionine, and also obtains it from dietary sources such as red meat and dairy products.

Ocarnix is used as a medicine to replace or supplement carnitine in patients who have primary carnitine deficiency, or secondary deficiency caused by certain metabolic disorders or by dialysis, so that normal energy metabolism from fatty acids can be restored.

Ocarnix belongs to the therapeutic class of amino-acid derivative / metabolic agents, and is specifically classified as a carnitine-replacement agent used to treat carnitine deficiency syndromes.

Levocarnitine plays an essential role in energy production by facilitating the transport of long-chain fatty acids across the inner mitochondrial membrane, where they undergo beta-oxidation to generate adenosine triphosphate (ATP). Levocarnitine also facilitates removal of excess short-chain and medium-chain fatty acyl groups from cells, helping to prevent their toxic accumulation.

In patients with primary or secondary carnitine deficiency, supplementation with Levocarnitine restores plasma and tissue carnitine concentrations, correcting the metabolic disturbances caused by impaired fatty-acid oxidation.

Oral Ocarnix tablets or solution should be swallowed with a glass of water, and may be taken with meals to improve tolerability and reduce body odor. Doses should be spaced evenly through the day as directed.

Intravenous Ocarnix should be administered only by or under the supervision of a healthcare professional, given as a slow intravenous injection or infusion; it should not be mixed in the same syringe or infusion line with other medicines unless compatibility is confirmed.

Ocarnix has a limited but clinically relevant interaction profile:

• Pivalate-conjugated antibiotics (e.g., pivampicillin): chronic use can deplete body carnitine stores, and co-administration with Ocarnix may be needed to correct resulting deficiency.
• Warfarin and other vitamin K antagonists: Ocarnix may potentiate anticoagulant effect in some patients; International Normalized Ratio (INR) should be monitored more closely when Ocarnix is started or stopped in a patient on warfarin.
• Anticonvulsants (e.g., valproic acid, phenytoin, phenobarbital): chronic use of these drugs can lower carnitine levels, which is one reason Ocarnix is sometimes co-prescribed; no dangerous interaction is expected, but levels should be monitored clinically.

Ocarnix is generally well tolerated. Reported side effects include:

Common

• Transient nausea and vomiting
• Abdominal cramps
• Diarrhea
• Unusual or "fishy" body odor

Uncommon / Rare

• New-onset seizures or increased seizure frequency in patients with or without a prior seizure disorder (see Precautions and Warnings)
• With intravenous Ocarnix: rare hypersensitivity/anaphylactoid-type reactions, transient hypertension or hypotension, and fever have been reported, mainly in dialysis patients

Ocarnix is a naturally occurring nutrient normally present in the body, including during pregnancy and lactation; however, data on supplemental Ocarnix use in pregnant or breastfeeding women are limited. As a general precaution, Ocarnix should be used during pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus. Ocarnix passes into breast milk in small amounts; a nursing mother should use Ocarnix only after consulting her physician, who will weigh the benefits and risks for her specific situation.

The following precautions apply to the use of Ocarnix:

• Seizure disorders: Ocarnix has rarely been associated with new-onset seizures or increased seizure frequency; use with caution in patients with a known seizure history, and monitor accordingly.
• Renal impairment / dialysis patients: dosing of Ocarnix should be individualized in these patients; high oral doses of Ocarnix can occasionally worsen diarrhea, which may affect fluid/electrolyte balance in vulnerable patients.
• Intravenous administration: should be given slowly by a healthcare professional, as rapid administration has rarely been associated with transient hypotension or hypertension and other infusion-related reactions.
• Hepatic impairment: use Ocarnix with caution and physician monitoring, as data in significant hepatic impairment are limited.

Reported effects of Ocarnix overdose are generally limited to an exaggeration of common side effects, such as diarrhea, nausea, vomiting, abdominal cramps, and a stronger fishy body odor. There is no specific antidote for Ocarnix overdose. If an overdose of Ocarnix is suspected, seek immediate medical attention or contact a poison control center/emergency services; treatment is supportive and symptomatic under medical supervision. Do not attempt home treatment for a suspected overdose.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. Do not use beyond the expiry date printed on the pack.

Renal impairment / dialysis: Intravenous Ocarnix dosing is specifically established for dialysis-dependent patients (see Dosage and Administration); dosing should be individualized based on dry body weight and clinical response.

Hepatic impairment: Limited data are available; use Ocarnix cautiously with physician monitoring.

Elderly patients: No specific dose adjustment is established for elderly patients, but they should be monitored as for any patient with reduced renal reserve.

Pediatric and geriatric use: see Pediatric Uses for details on children; general population safety in the elderly is comparable to adults when renal function is accounted for.

For primary or secondary carnitine deficiency, Ocarnix is typically used long-term/chronically, as deficiency states usually persist for life or for the duration of the underlying metabolic condition. For dialysis-related carnitine deficiency, Ocarnix is generally continued for as long as the patient remains on maintenance dialysis. Duration should be reviewed periodically by the treating physician based on carnitine levels and clinical response.

Amino acid derivative / Metabolic agent (Carnitine replacement therapy)

Levocarnitine acts as an essential cofactor in the transport of long-chain fatty acids from the cytoplasm into mitochondria via the carnitine palmitoyltransferase (CPT-I/CPT-II) shuttle system, where beta-oxidation of these fatty acids generates ATP for cellular energy. Levocarnitine also binds and helps to eliminate potentially toxic acyl-CoA groups that accumulate in certain metabolic disorders, converting them to acylcarnitines that are excreted in the urine, thereby restoring the free coenzyme-A pool needed for normal intermediary metabolism.

B

Ocarnix is an approved treatment for primary carnitine deficiency and for secondary carnitine deficiency due to inborn errors of metabolism in pediatric patients, including infants, using weight-based oral dosing (typically 50-100 mg/kg/day of Ocarnix in divided doses). Intravenous Ocarnix is used under specialist supervision for pediatric patients in acute metabolic crisis. For indications other than carnitine deficiency (e.g., adjunct uses), safety and efficacy of Ocarnix in children have not been established, and use should only occur under the direct guidance of a pediatric metabolic specialist.